288 related articles for article (PubMed ID: 7985476)
1. Mitoxantrone and standard dose cytosine arabinoside therapy in refractory or relapsed acute leukemia.
Keskin A; Tombuloğlu M; Atamer MA; Büyükkeçeci F
Acta Haematol; 1994; 92(1):14-7. PubMed ID: 7985476
[TBL] [Abstract][Full Text] [Related]
2. Mitoxantrone and continuous infusion of cytosine arabinoside in refractory and relapsed acute lymphoblastic leukemia.
Liso V; Specchia G; Capalbo S; Pavone V; Iacobazzi A; Iaculli ML; Dione R; Pansini N
Acta Haematol; 1992; 87(1-2):54-7. PubMed ID: 1585771
[TBL] [Abstract][Full Text] [Related]
3. High-dose cytosine arabinoside in combination with mitoxantrone for the treatment of refractory acute myeloid and lymphoblastic leukemia.
Hiddemann W; Kreutzmann H; Straif K; Ludwig WD; Mertelsmann R; Planker M; Donhuijsen-Ant R; Lengfelder E; Arlin Z; Büchner T
Semin Oncol; 1987 Jun; 14(2 Suppl 1):73-7. PubMed ID: 3473685
[TBL] [Abstract][Full Text] [Related]
4. Mitoxantrone and cytosine arabinoside in previously untreated adult patients with acute non-lymphocytic leukemia.
Osman I; Akin U; Ismet A; Meral B; Hamdi A; Haluk K
Haematologia (Budap); 1996; 27(2):93-7. PubMed ID: 14651226
[TBL] [Abstract][Full Text] [Related]
5. Treatment of refractory acute lymphoblastic leukemia in adults with high dose cytosine arabinoside and mitoxantrone (HAM).
Hiddemann W; Büchner T; Heil G; Schumacher K; Diedrich H; Maschmeyer G; Ho AD; Planker M; Gerith-Stolzenburg S; Donhuijsen-Ant R
Leukemia; 1990 Sep; 4(9):637-40. PubMed ID: 2395383
[TBL] [Abstract][Full Text] [Related]
6. Phase I clinical and pharmacokinetic evaluation of high-dose mitoxantrone in combination with cytarabine in patients with acute leukemia.
Feldman EJ; Alberts DS; Arlin Z; Ahmed T; Mittelman A; Baskind P; Peng YM; Baier M; Plezia P
J Clin Oncol; 1993 Oct; 11(10):2002-9. PubMed ID: 8410125
[TBL] [Abstract][Full Text] [Related]
7. Treatment of refractory or relapsed adult acute leukemia by using mitoxantrone-containing regimens.
Lin MT; Chen YC; Liu TW; Tien HF; Liu MC; Wang CH; Shen MC; Liu CH
Taiwan Yi Xue Hui Za Zhi; 1989; 88(11-12):1116-22. PubMed ID: 2636248
[TBL] [Abstract][Full Text] [Related]
8. A phase II study of high dose ARA-C and mitoxantrone for treatment of relapsed or refractory adult acute lymphoblastic leukemia.
Rosen PJ; Rankin C; Head DR; Boldt DH; Luthardt FW; Norwood T; Pugh RP; Karanes C; Appelbaum FR
Leuk Res; 2000 Mar; 24(3):183-7. PubMed ID: 10738999
[TBL] [Abstract][Full Text] [Related]
9. High-dose cytosine arabinoside and mitoxantrone in previously-treated acute leukemia patients.
Lejeune C; Tubiana N; Gastaut JA; Maraninchi D; Richard B; Launay MC; Sainty D; Sebahoun G; Carcassonne Y
Eur J Haematol; 1990 Apr; 44(4):240-3. PubMed ID: 2344886
[TBL] [Abstract][Full Text] [Related]
10. High-dose cytosine arabinoside and mitoxantrone: a highly effective regimen in refractory acute myeloid leukemia.
Hiddemann W; Kreutzmann H; Straif K; Ludwig WD; Mertelsmann R; Donhuijsen-Ant R; Lengfelder E; Arlin Z; Büchner T
Blood; 1987 Mar; 69(3):744-9. PubMed ID: 3469002
[TBL] [Abstract][Full Text] [Related]
11. Time sequential chemotherapy for primary refractory or relapsed adult acute myeloid leukemia: results of the phase II Gemia protocol.
Martino R; Guardia R; Altés A; Sureda A; Brunet S; Sierra J
Haematologica; 1999 Mar; 84(3):226-30. PubMed ID: 10189387
[TBL] [Abstract][Full Text] [Related]
12. Treatment of patients with recurrent and primary refractory acute myelogenous leukemia using mitoxantrone and intermediate-dose cytarabine: a pharmacologically based regimen.
Sternberg DW; Aird W; Neuberg D; Thompson L; MacNeill K; Amrein P; Shulman LN
Cancer; 2000 May; 88(9):2037-41. PubMed ID: 10813714
[TBL] [Abstract][Full Text] [Related]
13. Sequential intermediate-dose cytosine arabinoside and mitoxantrone for patients with relapsed and refractory acute myelocytic leukemia.
Paciucci PA; Cuttner J; Holland JF
Am J Hematol; 1990 Sep; 35(1):22-5. PubMed ID: 2202204
[TBL] [Abstract][Full Text] [Related]
14. Mitoxantrone and ara-C in previously treated patients with acute myelogenous leukemia.
Paciucci PA; Dutcher JP; Cuttner J; Strauman JJ; Wiernik PH; Holland JF
Leukemia; 1987 Jul; 1(7):565-7. PubMed ID: 3478540
[TBL] [Abstract][Full Text] [Related]
15. [High doses of cytosine arabinoside in the treatment of patients with acute relapsing or refractory leukemia].
Lobato-Mendizábal E; Ruiz-Argüelles GJ; Marín-López A
Rev Invest Clin; 1989; 41(2):139-45. PubMed ID: 2675236
[TBL] [Abstract][Full Text] [Related]
16. High antileukemic activity of sequential high dose cytosine arabinoside and mitoxantrone in patients with refractory acute leukemias. Results of a clinical phase II study.
Kern W; Schleyer E; Unterhalt M; Wörmann B; Büchner T; Hiddemann W
Cancer; 1997 Jan; 79(1):59-68. PubMed ID: 8988727
[TBL] [Abstract][Full Text] [Related]
17. Mitoxantrone and intermediate-dose cytarabine in relapsed or refractory acute myeloblastic leukemia.
Harousseau JL; Milpied N; Brière J; Desablens B; Ghandour C
Nouv Rev Fr Hematol (1978); 1990; 32(4):227-30. PubMed ID: 2290708
[TBL] [Abstract][Full Text] [Related]
18. Salvage therapy of refractory and relapsed acute leukemia with high dose mitoxantrone and high dose cytarabine.
Raanani P; Shpilberg O; Gillis S; Avigdor A; Hardan I; Berkowicz M; Sofer O; Lossos I; Chetrit A; Ben-Yehuda D; Ben-Bassat I
Leuk Res; 1999 Aug; 23(8):695-700. PubMed ID: 10456666
[TBL] [Abstract][Full Text] [Related]
19. Intensive consolidation chemotherapy for newly diagnosed acute myeloid leukemia using a regime containing moderate dose cytosine arabinoside and mitoxantrone.
Liang R; Chan TK; Chu YC; Chan J; Chan CH; Chiu E; Lie A; Kwong YL; Yeung YM; Chan LC
Anticancer Drugs; 1995 Apr; 6(2):224-8. PubMed ID: 7795271
[TBL] [Abstract][Full Text] [Related]
20. Mitoxantrone and cytosine arabinoside as treatment for acute myeloblastic leukemia in older patients.
MacCallum PK; Rohatiner AZ; Davis CL; Whelan JS; Oza AM; Lim J; Love S; Amess JA; Leahy M; Gupta RK
Ann Hematol; 1995 Jul; 71(1):35-9. PubMed ID: 7632817
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
